FOSTER CITY, Calif.--(BUSINESS WIRE)--APT, a specialty drug development company focused on effective treatments for significant unmet medical needs, announced today that it has entered into an exclusive licensing agreement with Novartis Pharma AG for the worldwide rights to develop and commercialize an inhalable form of cyclosporine for the prevention and treatment of lung transplant rejection.
